Deconstructing Moderna’s COVID-19 Patent Pledge
In the high-stakes market for COVID-19 vaccines, it is worth considering what motivates a private firm to relinquish valuable IP rights.| Bill of Health
In the high-stakes market for COVID-19 vaccines, it is worth considering what motivates a private firm to relinquish valuable IP rights.| Bill of Health
By Rebecca Canino, Anne R. Links, and Fawaz Al Ammary In the face of a growing organ donation crisis in the United States, characterized by a decline in donors and a surge in transplant waitlists, it has become increasingly clear that existing regulatory barriers impede access to critical transplant services. One solution lies in dismantling| Bill of Health
by Dana Northcraft and Natalie Birnbaum Since Roe v. Wade was overturned in June 2022, fourteen states and two territories have banned the provision of abortion care altogether.[i] Still, abortion rates in the United States are on the rise. This is in part due to the expansion of care delivery through telehealth for medication abortion| Bill of Health
by Leslie P. Francis Right at the end of its term, the Supreme Court evaded resolving a conflict between Idaho and the federal government about abortions in emergencies. The immediate conflict in Moyle v. United States is whether federal restrictions on Medicare funds may require hospitals to perform abortions needed to prevent significant deterioration of| Bill of Health
Month: August 2023| blog.petrieflom.law.harvard.edu
While egg freezing goes a long way toward relieving anxiety and sustaining hope, it also allows for conformity to heteropatriarchy and bionormativity.| Bill of Health - The blog of the Petrie-Flom Center at Harvard Law School
By Jorge L. Contreras On July 2, 2024, the High Court of the United Kingdom issued a decision in Moderna’s mRNA vaccine patent litigation against Pfizer and BioNTech. As I previously discussed in October of 2020, Moderna pledged not to enforce its patents against makers of COVID-19 vaccines during the pandemic. Then, in 2022, Moderna| Bill of Health
Month: June 2024| blog.petrieflom.law.harvard.edu
by Barbara Pfeffer Billauer Legal pundits are predicting the imminent demise (or at least substantial enfeeblement) of the Chevron doctrine. Until recently, that case afforded substantial judicial deference to decisions made by administrative agencies if a statutory provision under its purview was ambiguous. Now two cases are before the Supreme Court challenging an agency interpretation| Bill of Health - The blog of the Petrie-Flom Center at Harvard Law School
by Victoria Litman, M.Div., J.D., LL.M. On May 21, 2024, the Drug Enforcement Administration (DEA) published a Notice of Proposed Rulemaking (NPRM) signed by Attorney General Merrick Garland in the Federal Register. This publication kicks off a 62-day comment period on a rule that would move marijuana to Schedule 3 of the Controlled Substances Act| Bill of Health
